PTC Therapeutics Inc (PTCT) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

Total Cash From Operating Activities Chart for PTC Therapeutics Inc

PTC Therapeutics Inc (PTCT) operating cash flow for FY2025 was USD 711.2M. PTC Therapeutics Inc's operating cash flow moved from USD -20.8M in 2011 to USD 711.2M in 2025 over 14 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$4.94B
Implied Share Price
$59.24
Enterprise Value
$3.67B
Revenue (TTM)
$1.01B
EBITDA
$171.22M
Profit Margin
-3.81%
Trailing P/E
—
Forward P/E
22.73
Price/Book (MRQ)
1743.27
Price/Sales (TTM)
4.90
EV/EBITDA
21.15
EV/Revenue
3.64
Dividend Yield
—
Book Value
$-1.99
Free Cash Flow (FY2025)
$411.18M
Free Cash Flow Yield
8.32%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.